Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 16.50 and last traded at GBX 16.25, with a volume of 4783882 shares. The stock had previously closed at GBX 15.10.
Scancell Stock Performance
The company has a market cap of £168.64 million, a P/E ratio of -29.55 and a beta of 0.45. The firm has a 50 day moving average of GBX 12.59 and a 200-day moving average of GBX 11.47. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Articles
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
